Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Trevena, Inc. (TRVN)

1.66   -0.02 (-1.19%) 02-03 15:39
Open: 1.68 Pre. Close: 1.68
High: 1.7299 Low: 1.58
Volume: 157,761 Market Cap: 13(M)

Technical analysis

as of: 2023-02-03 3:21:12 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 2.26     One year: 2.69
Support: Support1: 1.33    Support2: 1.1
Resistance: Resistance1: 1.93    Resistance2: 2.3
Pivot: 1.81
Moving Average: MA(5): 1.66     MA(20): 1.84
MA(100): 3.13     MA(250): 6.4
MACD: MACD(12,26): -0.2     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 9.3     %D(3): 9.7
RSI: RSI(14): 36.4
52-week: High: 15.27  Low: 0.25
Average Vol(K): 3-Month: 93 (K)  10-Days: 73 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ TRVN ] has closed above bottom band by 16.3%. Bollinger Bands are 56.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.76 - 1.77 1.77 - 1.77
Low: 1.62 - 1.63 1.63 - 1.65
Close: 1.66 - 1.68 1.68 - 1.7

Company Description

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

Headline News

Tue, 31 Jan 2023
Humane Society faces increased demand - The Carroll News

Tue, 17 Jan 2023
Is Trevena Inc (TRVN) a Stock to Watch After Gaining 17.98% This Week? - InvestorsObserver

Thu, 12 Jan 2023
Trevena Enrolls First Subject in TRV045 Proof-of-Concept Trial ... - MyChesCo

Mon, 09 Jan 2023
Trevena Enrolls First Subject in TRV045 Proof-of-Concept Trial ... - GlobeNewswire

Tue, 29 Nov 2022
Trevena Regains Compliance with Nasdaq Listing Requirements - Yahoo Finance

Wed, 16 Nov 2022
Trevena Launches $8 Million Registered Direct Stock Offering; Shares Fall - Marketscreener.com

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 165 (M)
% Held by Insiders 1.7142e+008 (%)
% Held by Institutions 1.4 (%)
Shares Short 3,430 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -5.858e+007
EPS Est Next Qtl -0.32
EPS Est This Year -1.37
EPS Est Next Year -0.94
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -29
Return on Assets (ttm) 500
Return on Equity (ttm) -41.7
Qtrly Rev. Growth 200000
Gross Profit (p.s.) 0
Sales Per Share -49.99
EBITDA (p.s.) -206952
Qtrly Earnings Growth -0.3
Operating Cash Flow 0 (M)
Levered Free Cash Flow -54 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.04
Price to Cash Flow 4.63

Stock Dividends

Dividend 0
Forward Dividend 3.22e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.